Filing Details
- Accession Number:
- 0001562180-23-001533
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-02-17 18:09:58
- Reporting Period:
- 2023-02-15
- Accepted Time:
- 2023-02-17 18:09:58
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1395937 | Syndax Pharmaceuticals Inc | SNDX | Pharmaceutical Preparations (2834) | 320162505 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1594274 | Peter Ordentlich | C/O Syndax Pharmaceuticals, Inc. 35 Gatehouse Drive, Building D, Floor 3 Waltham MA 02451 | Chief Scientific Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-02-15 | 7,572 | $6.38 | 7,572 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-02-15 | 7,572 | $25.84 | 0 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2023-02-15 | 17,428 | $7.20 | 17,428 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-02-15 | 17,428 | $25.84 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (Right to buy) | Disposition | 2023-02-15 | 17,428 | $25.84 | 17,428 | $7.20 |
| Common Stock | Stock Options (Right to buy) | Disposition | 2023-02-15 | 7,572 | $25.84 | 7,572 | $6.38 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2025-06-01 | No | 4 | M | Direct | |
| 0 | 2029-02-06 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 443,841 options to purchase shares of common stock that are vested and immediately exercisable and a total of 202,500 options to purchase shares of common stock that have not yet vested.
- The sale prices ranged from $25.53 to $26.10.
- This option is fully vested.
Billionaire Hedge Funds
